Published online Sep 26, 2021. doi: 10.4330/wjc.v13.i9.483
Peer-review started: March 10, 2021
First decision: May 6, 2021
Revised: May 25, 2021
Accepted: July 26, 2021
Article in press: July 26, 2021
Published online: September 26, 2021
The time in therapeutic range (TTR) is a quality measure for anticoagulation therapy with warfarin.
TTR of international normalized ratio (INR) needs to be achieved with a percentage of ≥ 60% for patient to receive a maximal benefit from warfarin such as preventing stroke, major bleeding, and even death.
TTR and the predictors of poor TTR need to be evaluated among atrial fibrillation (AF) patients that received warfarin therapy.
Eligible patients with AF from January 2014 to December 2018 for INR monitoring were included in this study. Demographic data, indication of warfarin therapy, INR target, and percentage of INR within range were collected using a data collection form. TTR was assessed using Rosendaal method.
In patients with AF, the mean TTR was 60.6% with the highest TTR score achieved in 2018, with a percentage of 67.3%.
This study showed that high HAS-BLED score was associated to poor TTR.
Patients with AF and high HAS-BLED score may have less benefit from warfarin therapy. Thus, other alternative oral anticoagulants should be considered for maxi